Investors hope AmSurg
What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on AmSurg with seven of 10 analysts rating it hold. Analysts like AmSurg better than competitor LCA-Vision overall. Zero out of one analysts rate LCA-Vision a buy compared to one of 10 for AmSurg.
- Revenue forecasts: On average, analysts predict $213.7 million in revenue this quarter. That would represent a rise of 15.7% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.46 per share. Estimates range from $0.41 to $0.47.
What our community says:
CAPS All-Stars are solidly behind the stock, with 95% granting it an "outperform" rating. The community at large is in line with the All-Stars, with 94.7% assigning it a rating of "outperform." Despite the majority sentiment in favor of AmSurg, the stock has a middling CAPS rating of three out of five stars.
AmSurg's income has fallen year-over-year by an average of 7.5% over the past five quarters. Revenue has now gone up for three straight quarters.
For all our AmSurg-specific analysis, including earnings and beyond, add AmSurg to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.